Early Feasibility Study (EFS) of the 'CAROL' for Treatment of Lung Cancer Stage 1

This study aims to evaluate the safety of the CAROL device for treating lung tumors in patients diagnosed with non-small cell lung cancer (NSCLC) with tumor size ≤ 2 cm (cT1b). The primary objective is to assess safety by monitoring and grading adverse events using the CTCAE v5.0 criteria at one month following the procedure.

Trial Details

NCT ID
NCT07122258
Phase
NA
Sponsor
Tau Medical Australia Pty Ltd
Status
RECRUITING
Cancer Type
Lung Cancer
Interventions
  • CAROL NSCLC treatment Device
Locations (sample)
  • Melbourne, Victoria, Australia|-37.814,144.96332

Key Eligibility Criteria

  • Those who meet all the following criteria are eligible to participate in the clinical trial.
  • Adults 18 years of age or older at the time of screening
  • NSCLC tumour(s)≤ 2 cm (cT1b) suitable for resection
  • Suitable candidate for resection per standard of practice (Lobectomy)

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Lung Cancer Trials on Trialify →